Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 05, 2023

Outcomes Associated With HER2DX ERBB2 mRNA Expression in Patients With Advanced HER2+ MBC Treated With T-DM1

Journal of the National Cancer Institute


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the National Cancer Institute
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
J. Natl. Cancer Inst 2022 Dec 28;[EPub Ahead of Print], F Brasó-Maristany, G Griguolo, N Chic, T Pascual, L Paré, J Maues, P Galván, MV Dieci, F Miglietta, T Giarratano, O Martínez-Sáez, M Marín-Aguilera, F Schettini, B Conte, L Angelats, M Vidal, B Adamo, M Muñoz, E Sanfeliu, B González, A Vivancos, P Villagrasa, JS Parker, CM Perou, P Conte, A Prat, V Guarneri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading